Neurocrine is launching a new sprinkle formulation of Ingrezza – valbenazine – capsules, indicated for the treatment of adults with tardive dyskinesia and chorea associated with Huntington’s disease. Ingrezza Sprinkle capsules is now available through the same network of specialty and local affiliated pharmacies that distribute Ingrezza. Neurocrine Biosciences received FDA approval of Ingrezza Sprinkle on April 30 of this year.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $170 from $160 at Morgan Stanley
- Neurocrine price target raised to $173 from $169 at JPMorgan
- Jefferies says Neurocrine, Alkermes not seeing Sublocade-like impact on Medicaid
- Neurocrine announces FDA accepted two NDAs
- Neurocrine presented CAHtalyst Phase 3 studies at ENDO 2024